|
ZNF773 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.55120000031739E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.21049999996159E-06 |
| Normal-vs-Stage2 |
3.199700E-03 |
| Normal-vs-Stage3 |
1.27319999987385E-07 |
| Normal-vs-Stage4 |
2.49409999986128E-07 |
| Stage1-vs-Stage2 |
2.454200E-01 |
| Stage1-vs-Stage3 |
7.118100E-02 |
| Stage1-vs-Stage4 |
1.062810E-01 |
| Stage2-vs-Stage3 |
2.897600E-02 |
| Stage2-vs-Stage4 |
3.453800E-02 |
| Stage3-vs-Stage4 |
8.334400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44330000015647E-07 |
| Normal-vs-AfricanAmerican |
2.360800E-03 |
| Normal-vs-Asian |
3.414000E-04 |
| Caucasian-vs-AfricanAmerican |
6.372000E-01 |
| Caucasian-vs-Asian |
2.032800E-01 |
| AfricanAmerican-vs-Asian |
6.663600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.01429999999725E-05 |
| Normal-vs-Female |
5.8295000004982E-07 |
| Male-vs-Female |
3.569600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.95689999993709E-07 |
| Normal-vs-Age(41-60Yrs) |
1.68877999999761E-05 |
| Normal-vs-Age(61-80Yrs) |
8.5721999998345E-07 |
| Normal-vs-Age(81-100Yrs) |
2.501800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.546000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.912200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.168000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.654600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.492800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.571200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.902800E-03 |
| Classical-VS-Follicular |
8.894000E-01 |
| Classical-VS-Other |
4.178200E-01 |
| Classical-VS-Normal |
1.75506999999797E-05 |
| Tall-VS-Follicular |
1.998390E-02 |
| Tall-VS-Other |
6.020600E-01 |
| Tall-VS-Normal |
2.29430000553421E-08 |
| Follicular-VS-Other |
5.626000E-01 |
| Follicular-VS-Normal |
4.44250000000146E-05 |
| Other-VS-Normal |
2.149700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.43800000030181E-07 |
| Normal-vs-N1 |
3.98939999923797E-08 |
| N0-vs-N1 |
1.533940E-02 |
|
|
